Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS) SHH
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
Mabwell (Shanghai) Bioscience Co., Ltd.
Address
Building 2 Room 105, No. 230 Cailun RoadChina (Shanghai) Pilot Free Trade Zone Shanghai, 201210China
Shanghai, 201210
China
Phone
86 21 5833 2260
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1416
First IPO Date
January 18, 2022
Key Executives
| Name | Title | Pay | Year Born |
| Datao Liu | Chairman, Chief Executive Officer & GM | 2.43M | 1972 |
| Xun Gui | Vice President, Deputy GM & Director | 1.84M | 1986 |
| Huiguo Hu | Senior VP, CCO, Deputy GM, Secretary of the Board & Director | 2.12M | 1977 |
| Hai Wu | Deputy GM, President of R&D and Director | 3.7M | 1974 |
| Xin Du | Chief Scientific Officer & President of Maiwei (US) | 0 | 1972 |
| Kwan Wai Leung | Joint Company Secretary | 0 | 1983 |
| Chunshan Tang | Executive Director | 0 | 1969 |
| Yinhan Guo | Chief Research & Development Officer | 0 | 1971 |
| Jinchao Zhang | Deputy General Manager | 0 | 1972 |
| Jun Hua | Vice President, Chief Financial Officer & Deputy GM | 0 | 1981 |
| Shu Hai Wang | Deputy GM & Chief Medical Officer | 0 | 1974 |
Description
Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.
